Semaglutide for Weight Loss in Obesity
(STEP UP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new weight loss drug called semaglutide on overweight or obese individuals. The drug helps reduce hunger and increase fullness, promoting weight loss. Participants' progress will be monitored over a period of time. Semaglutide is a long-acting GLP-1 receptor agonist that has been shown to induce significant weight loss in individuals with obesity or overweight.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are on glucose-lowering medications, you must stop them at least 90 days before the screening.
Is semaglutide safe for weight loss in humans?
Semaglutide has been shown to be generally safe in humans, with studies indicating it is well-tolerated and effective for weight loss and managing type 2 diabetes. It has been tested in various forms, including oral and injectable, and has demonstrated cardiovascular safety comparable to placebo in high-risk patients.12345
How is the drug semaglutide unique for weight loss in obesity?
What data supports the effectiveness of the drug Semaglutide for weight loss in obesity?
Who Is on the Research Team?
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
This trial is for adults with obesity (BMI ≥ 30 kg/m²) who have tried and failed to lose weight through dieting. It's not open to people with a personal or family history of certain thyroid cancers, those treated with diabetes medications recently, or anyone whose weight changed by more than 11 pounds in the last 90 days.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive once-weekly injections of semaglutide or placebo, with dose escalation over 20 weeks followed by maintenance dosing for a total of 72 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- Semaglutide
Semaglutide is already approved in European Union, United States, Canada, Japan for the following indications:
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Obesity
- Type 2 diabetes
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen